New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07175233

Not yet recruiting Disease control Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new injectable drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema) that needs systemic treatment. About 184 participants will receive either a low, medium, or high dose of SIM0278 or a placebo. The main goal is to see how much eczema symptoms improve after 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIM0278 injection
What this could lead to: If successful, this could lead to a new treatment option for people with moderate to severe eczema that is not well controlled by current therapies.
What could go wrong: This is an early Phase 2 trial with only 184 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University

Hangzhou, China
The First Hospital of China Medical University

Shenyang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.